1. Inactivation mechanisms of influenza A virus under pH conditions encountered in aerosol particles as revealed by whole-virus HDX-MS (vol 8, e00226-23, 2023) 

   David, Shannon C.; Vadas, Oscar; Glas, Irina; et al. (2024)

   MSPHERE

   Other Journal Item

2. Spatiotemporal Characteristics and Triggers of Flash Droughts across All the River Basins in India 

   Poonia, Vikas; Jha, Srinidhi; Srinivas, V. V.; et al. (2024)

   Journal of Hydrometeorology

   Flash droughts (FDs) have attracted widespread attention in recent years due to their sudden onset and rapid intensification with significant impacts on ecosystems, water resources, and agriculture. These features of FDs pose unique challenges for their forecast, monitoring, and mitigation. The impact of FDs on society can vary depending on several factors, such as the frequency of their occurrence, rate of intensification, and mean ...

   Journal Article

3. Charge-Tagged Cyclopentadienone Iron Complexes: Mechanistic Studies Using Mass Spectrometry for Catalytic Hydrogenation Reactions 

   Bütikofer, André (2024)

   Cyclopentadienone iron complexes, also referred to as Knölker catalysts, have emerged as promising catalysts for the reduction of ketones, aldehydes, and imines. They constitute the iron analogues to the ruthenium based Shvo catalysts and offer the possibility to enable the same chemistry as the ruthenium based system with use of a widely available first-row transition metal. While there is a consensus on the operating reaction ...

   Doctoral Thesis

4. Development of Anti-L1CAM Cancer Stem Cell-Targeted Radioimmunotherapy and Study of L1CAM-associated Mechanisms of Radioresistance 

   Todorov, Tihomir (2024)

   Doctoral Thesis

5. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics 

   Raeber, Miro E.; Caspar, Dominic P.; Zurbuchen, Yves; et al. (2024)

   Immunity

   Due to its stimulatory potential for immunomodulatory CD4⁺ regulatory T (Treg) cells, low-dose interleukin-2 (IL-2) immunotherapy has gained considerable attention for the treatment of autoimmune diseases. In this investigator-initiated single-arm non-placebo-controlled phase-2 clinical trial of low-dose IL-2 immunotherapy in systemic lupus erythematosus (SLE) patients, we generated a comprehensive atlas of in vivo human immune responses ...

   Journal Article

View more